Watson introduces new oral contraceptive, Vestura

Download PDF Copy

Jan 18 2012

NewsGuard 100/100 Score

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product. Watson began shipping the product today. Watson's Vestura(TM) is indicated for the prevention of pregnancy and for the treatment of moderate acne in women at least 14 years old only if the patient desires an oral contraceptive for birth control.

Yaz(R) and its generic versions had total U.S. sales of approximately $510 million for the twelve months ending November 30, 2011, according to IMS Health.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Women's Health News | Pharmaceutical News

Tags: Acne, Birth Control, Contraceptive, Estradiol, Healthcare, Medicaid, Medicare, Pharmaceuticals, Pregnancy, Urology

Comments (0)

Download PDF Copy

Suggested Reading

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Study finds oral contraceptives may alter glycemic response in women using androgenic pills

Study finds oral contraceptives may alter glycemic response in women using androgenic pills

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Antibiotic resistance threatens millions of lives worldwide